The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.
Novel Drug Shows Increased Efficacy in Small Metastatic CRC Population
February 6th 2024Results from part 3 of the phase 2a CORIST trial found that combining SCO-101 with chemotherapy improved the progression-free survival and clinical benefit rate in patients with metastatic colorectal cancer.